The vascular endothelial growth factor (VEGF) pathway plays a critical role in driving oncoangiogenesis in lung cancer and dual inhibition of VEGF signaling and EGFR signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy and overcoming EGFR-TKI resistance.13 This evidence concerns the gene VEGFA and lung cancer.